Abstract Pathogenic germline mutations in the BRCA1 gene predispose carriers to early onset breast and ovarian cancer. Clinical genetic screening of BRCA1 often reveals variants with uncertain clinical significance, complicating patient and family management. Therefore, functional examinations are urgently needed to classify whether these uncertain variants are pathogenic or benign. In this study, we investigated 14 BRCA1 variants by in silico splicing analysis and mini-gene splicing assay. All 14 alterations were missense variants located within the BRCT domain of BRCA1 and had previously been examined by functional analysis at the protein level. Results from a validated minigene splicing assay indicated that nine BRCA1 variants resulted in splicing aberrations leading to truncated transcripts and thus can be considered pathogenic (c.
Introduction
Germline mutations in the BRCA1 (MIM 113705) tumor suppressor gene confer an increased lifetime risk of breast and ovarian cancer. The absolute risk of cancer by the age of 70 years conferred by BRCA1 mutations in female carriers is reported to be between 60 and 71 % for breast cancer and between 39 and 59 % for ovarian cancer [1] [2] [3] [4] . Mutational screening has identified a large number of pathogenic BRCA1 mutations in women with a family history of breast and/or ovarian cancer. Unfortunately, a substantial proportion of the sequence alterations identified during routine genetic testing are in-frame deletions/insertions, missense, silent, and intronic variants of uncertain clinical significance (VUS). A number of 1273 BRCA1 VUS's have been reported by the ENIGMA (EvidenceBased Network for the Interpretation of Germline Mutant Alleles) consortium (up until September 2010) [5] . Of these, the majority are missense variants, constituting a number of 781 unique variants. The identification of a VUS is associated with a complicated cancer risk assessment, genetic counseling, and clinical management of the patients and their families. Because most VUS occur at very low population frequencies, direct epidemiological measures, such as association studies, are often not adequately powerful to identify the variants associated with cancer predisposition [6] . A promising approach is to add functional studies to characterize the biological effect of the variants and thereby provide clinicians with a better framework for counseling and treatment. It has been shown that a large portion of BRCA1 variants induce splicing defects [7] . Ideally, RNA from a patient should be examined by RT-PCR analysis to establish if a variant has an effect on splicing. However, in many cases, RNA is not available from the patient. Alternatively, the sequence variant can be examined by mini-gene splicing analysis, which has been shown to be a valid method for investigating the impact of an alteration on the splicing pattern [8, 9] . Here, we report the functional characterization of 14 BRCA1 variants using in silico splicing analysis and a validated mini-gene splicing assay [10] . All 14 variants were located in close proximity to splice donor/acceptor sites in the highly conserved BRCT domain and had previously been investigated by protein folding, phosphopeptide-binding, and cell-based transcriptional assays [11] . The BRCT domain plays a critical role in tumor suppression and is considered to be one of two regions to contain the vast majority of cancer-associated mutations [12] [13] [14] [15] [16] . In summary, our study classified nine BRCA1 variants as pathogenic as these variants affect mRNA splicing leading to out-of-frame exon skipping or the use of cryptic splice sites resulting in truncated transcripts, while five BRCA1 variants were shown to have no effect on splicing.
Materials and methods

Variant nomenclature
All missense variants were selected from the Breast Cancer Information Core (BIC) database [17] and the literature [11] based on the close proximity to the splice acceptor and splice donor sites. The BRCA1 variants are numbered according to the guidelines from the Human Genome Variation Society (http://www.hgvs.org/mutnomen) using NCBI Reference Sequence NG_005905.2.
In silico analysis
The following five splice site prediction programs were used to predict the effect of variants on the efficiency of splicing: Splice Site Finder (http://www.interactive-biosoftware. com); GeneSplicer (http://www.cbcb.umd.edu/software/ GeneSplicer); Splice Site Prediction by Neural Network (http://www.fruitfly.org/seq_tools/splice.html); MaxEntScan (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_ scoreseq.html); and Human Splicing Finder (http://www. umd.be/HSF/). The analysis was performed by the integrated software Alamut version 2.4 (http://www.interactive-bio software.com) using default settings in all predictions. A variation of more than 10 % in at least two algorithms was considered as having an effect on splicing [9] .
Mini-gene splicing assay
Wild-type BRCA1 exons were cloned into the pSPL3 vector ( Fig. 1 ) and single nucleotide substitutions were introduced by mutagenesis performed using Finnzymes' Phusion High-Fidelity polymerase according to the accompanying instructions. Wild-type and mutant constructs were transfected in duplicate into COS-7 cells as recently described [10] . Cells were harvested after 48 h and total RNA was extracted using Trizol reagent (Invitrogen). cDNA was synthesized using 1 lg of total RNA, M-MuLV reverse transcriptase polymerase (New England Biolabs), and 20 lM of nucleotide oligo(dT) 15 primer. cDNA was amplified with Phusion DNA polymerase using the primers dUSD2 (5 0 -TCTGAGTCACCTGGACAACC-3 0 ) and dUSA4 (5 0 -ATCTCAGTGGTATTTGTGAGC-3 0 ). PCR products were separated by electrophoresis on a 1 % agarose gel containing ethidium bromide and quantified using Image Lab 2.0 software (Bio-Rad) (Fig. 2) . Each DNA band was gel purified using GE Healthcare's Illustra GFX PCR DNA and Gel Band Purification Kit and sequenced with the dUSD2 and dUSA4 primers.
Results
Previous studies have shown that a large portion of BRCA1 variants induce splicing defects [7] . In the present study, 14 BRCA1 variants located near splice acceptor or donor sites in the conserved BRCT domain were examined using in silico splicing analysis and a validated mini-gene splicing assay [7, 10] (Table 1 ). The in silico splicing analysis was performed using five different splice site prediction programs which predict changes in splice site strength. The applicable threshold was a variation between the wild-type and the variant score of more than 10 % in at least two different algorithms [9] . According to this criterion, 10 The functional effects of all 14 BRCA1 variants on mRNA splicing were subsequently examined by mini-gene splicing assays. Each construct was transfected into COS-7 cells in duplicate and cells were harvested. mRNA was then purified and analyzed by RT-PCR. Finally, PCR products were visualized by ethidium bromide staining of 1 % agarose gels ( variants presented with a very weak wild-type band at 265 bp constituting 7 % and 17.5 % of the total amount of transcript, respectively (Fig. 2b) . Wild-type BRCA1 exon 21 generated one transcript at the expected 232 bp, while the c.5332G[A/ p.Asp1778Asn and c.5332G[T/p.Asp1778Tyr variants resulted in one strong band of 177 bp excluding exon 21 (Fig. 2d) . Finally, wild-type BRCA1 exon 23 revealed a single transcript at the expected size of 238 bp, while c.5408G[C/p.Gly1803Ala resulted in one strong band of 177 bp lacking exon 23 (Fig. 2f) . In contrast to the in silico splicing data, c.5153G[C/p.Trp1718Ser (Fig. 2c) (Fig. 2a-d) showed no difference in size or intensity of the bands between wild-type and mutant constructs.
Discussion
Genetic screening for pathogenic mutations in breast and ovarian cancer genes BRCA1 and BRCA2 is common practice for individuals from high-risk families. However, the test often results in identification of a VUS, leading to impeded cancer risk estimation and clinical management [18] . Therefore, it is important to classify all identified BRCA1/BRCA2 sequence variants [19] . It has previously been established that all variation types in BRCA1 can lead to splicing abnormalities [7] . Hence, it is important to include investigations at the RNA level when classifying a variant.
In this study, we examined 14 BRCA1 variants located in close proximity to the exon-intron boundary regarding their effect on mRNA splicing using in silico splicing analysis along with a validated mini-gene splicing assay [10] . All variants are very rare in the general population, and only two of the variants (c. [20] .
Six [11] , while in silico and functional studies showed that the c.5074G[A/p.Asp1692Asn variant, previously reported as an Icelandic founder mutation [23] , had low or no impact on the protein level [11, 22, 24] . The c.5074G[T/p.Asp1692Tyr variant has been predicted to have an effect on the protein level by in silico analysis [21, 22] as well as in one functional assay based on measurement of the thermodynamic stability of the BRCA1 BRCT domain [22] , while other functional assays based on proteolysis, phosphopeptide-binding, and transcription assays were inconclusive [11] . In this study, the c. Fig. 2 The thresholds represent score predicted for wild-type sequence/score predicted for mutated sequence. The scores indicate the values for splice donor (SD) or splice acceptor (SA) sites, respectively. Changes relative to wild-type sequences are indicated in % NI not identified cryptic splice site has previously been reported for the c.5074G[C/p.Asp1692His variant using lymphoblastoid cell lines (LCLs) or patient blood samples [25, 26] . The two variants, c.5332G[A/p.Asp1778Asn and c.5332G[T/p.Asp1778Tyr, located in exon 21 near the exon-intron boundary also resulted in out-of-frame exon skipping (Fig. 2d) and hence are classified as pathogenic. The c.5332G[A/p.Asp1778Asn variant is reported once in the BIC database as a VUS, whereas the c.5332G[T/ p.Asp1778Tyr variant has not previously been reported. Our data regarding the c.5332G[A/p.Asp1778Asn variant are in agreement with recent splicing data using RNA from patient blood samples [27] . Both the c.5332G[A/ p.Asp1778Asn variant and the c.5332G[T/p.Asp1778Tyr variant have previously been shown to have no effect on protein level using functional assays and in silico analysis [11, 12, 21, 22] .
The final variant that showed aberrant splicing using the mini-gene splicing assay was c.5408G[C/p.Gly1803Ala (Fig. 2f) . This variant caused out-of-frame skipping of exon 23 of BRCA1. The c.5408G[C/p.Gly1803Ala variant has been reported three times in the BIC database as a VUS and functional studies as well as in silico analysis showed that the variant had an uncertain or no effect on the protein level [11, 21] .
The (Fig. 2a-c, e) . This result was in accordance with the in silico splicing prediction except for the c.5153G[C/p.Trp1718Ser variant which was suggested to affect splicing by all the programs used ( Table 1 ). All five variants are reported in the BIC database as VUS. Three variants (c.5072C[A/p.Thr1691Lys, c.5153G[C/p.Trp1718Ser, and c.5154G[T/p.Trp1718Cys) have been shown to have a strong functional effect on the protein level [11] . In addition, structural examination of c.5072C[A/p.Thr1691Lys showed that the alteration significantly disturbed the surface of the binding pocket interacting with the BACH1 phosphorylated peptide [28] [29] [30] . Both c.4985T[C/p.Phe1662Ser and c.5333A[G/p.Asp177 8Gly missense variants have been reported to have a low functional effect on the protein level [11] . In addition, the c.4985T[C/p.Phe1662Ser variant has previously been classified as a variant of no clinical significance based on in silico analysis [31] . Finally, the c.5333A[G/p.Asp1778Gly variant has previously been tested for its effect on mRNA splicing using LCLs or patient blood samples [25, 32] , and the results are in agreement with the result shown in Fig. 2e .
The mini-gene assay used in this study has recently been validated and showed a 100 % concordance with results using patient blood samples [10] . However, there are limitations using a mini-gene assay, since the assay examine the expression of an artificial transcript usually containing one exon and varying amounts of flanking intron sequences, compared to assessing the natural endogenous expression of BRCA1 transcripts. The use of mini-gene constructs containing only one exon will moreover miss more complex changes (e.g. skipping of more exons). Finally, the COS-7 cell line used in the mini-gene assay may not fully reflect the splicing machinery used in breast tissue. However, since BRCA1 alternative splicing is similar in breast tissue and blood samples [33] , and the use of COS-7 cells showed a 100 % concordance with results using patient blood samples [10] , we infer that the basal splicing machinery necessary for correct BRCA1 splicing is present in COS-7 cells.
Another caveat is the finding that natural occurring BRCA1 isoforms lacking exons 17, 21, and 23 exist [33] . 5) even though minor amounts of naturally occurring transcripts lacking these exons exist.
In conclusion, using in silico splicing prediction and a validated mini-gene splicing assay, we classified nine [T/p.Asp1778Tyr, and c.5408G[C/p.Gly1803Ala), since the variants affected mRNA splicing leading to out-offrame exon skipping or the use of cryptic splice sites resulting in truncated transcripts. All nine variants had previously been investigated at the protein level but only one of the variants (c.5072C[T/p.Thr1691Ile) showed a strong functional effect [11, 21] . The remaining five BRCA1 variants (c.4985T[C/p.Phe1662Ser, c.5072C[A/p.Thr169 1Lys, c.5153G[C/p.Trp1718Ser, c.5154G[T/p.Trp1718Cys, and c.5333A[G/p.Asp1778Gly) had no effect on splicing when examined by the mini-gene splicing assay. However, three of these variants (c.5072C[A/ p.Thr1691Lys, c.5153G[C/p.Trp1718Ser, and c.5154G[ T/p.Trp1718Cys) had previously been shown to have a strong functional effect on the protein level [11] . Our results clearly demonstrate the relevance of assessing missense variants for possible splicing defects before final classification. However, the splicing data should, when possibly, be combined with multifactorial likelihood analysis, based on co-segregation, family history, tumor pathology, and co-occurrence with a pathogenic BRCA1 mutation to support the conclusions before the findings are used in the clinic.
